EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure

K M Rifat Faysal, James C Walsh, Nadine Renner, Chantal L Márquez, Vaibhav B Shah, Andrew J Tuckwell, Michelle P Christie, Michael W Parker iD, Stuart G Turville iD, Greg J Towers iD, Leo C James iD, David A Jacques iD und 1 weitere

eLife · 2024

DOI: 10.7554/elife.83605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von K M Rifat Faysal und 12 weiteren Autor:innen. Beteiligte Einrichtung: EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, UNSW, Sydney, Australia. Hauptthemen laut MEDLINE: HIV-1, Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the effect of lenacapavir on HIV capsid stability and uncoating. We employ a single particle approach that simultaneously measures capsid content release and lattice persistence. We demonstrate that lenacapavir’s potent antiviral activity is predominantly due to lethal hyperstabilisation of the capsid lattice and resultant loss of compartmentalisation. This study highlights that disrupting capsid metastability is a powerful strategy for the development of novel antivirals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Anti-HIV AgentsHIV InfectionsHumansCapsidCapsid Proteins

Stichwörter der Autor:innen

HIV-1capsiddrug mechanism of actioninfectious diseasemicrobiologymolecular biophysicsnonestructural biology

Substanzen

Capsid ProteinsAnti-HIV Agents

Autor:innen und Institutionen

  • EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, UNSW, Sydney, Australia.
  • MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
  • Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia.
  • Structural Biology Unit, St. Vincent's Institute of Medical Research, Fitzroy, Australia.
  • The Kirby Institute, UNSW, Sydney, Australia.
  • Division of Infection and Immunity, University College London, London, United Kingdom.

ORCID-Profile: Michael W Parker, Stuart G Turville, Greg J Towers, Leo C James, David A Jacques, Till Böcking

Förderung

  • Wellcome Trust
  • Medical Research Council
  • National Health and Medical Research Council
  • Australian Research Council

Zitieren

APA

Faysal, K. M. R., Walsh, J. C., Renner, N., Márquez, C. L., Shah, V. B., Tuckwell, A. J., Christie, M. P., Parker, M. W., Turville, S. G., Towers, G. J., James, L. C., Jacques, D. A., & Böcking, T. (2024). Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure. eLife. https://doi.org/10.7554/elife.83605

Vancouver

Faysal KMR, Walsh JC, Renner N, Márquez CL, Shah VB, Tuckwell AJ, et al. Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure. eLife. 2024. doi:10.7554/elife.83605

BibTeX
@article{Faysal2024,
  author = {Faysal, K M Rifat and Walsh, James C and Renner, Nadine and Márquez, Chantal L and Shah, Vaibhav B and Tuckwell, Andrew J and Christie, Michelle P and Parker, Michael W and Turville, Stuart G and Towers, Greg J and James, Leo C and Jacques, David A and Böcking, Till},
  title = {Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.83605}
}
Kostenlos starten →